Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA OKs Teleflex's Ringer Perfusion Balloon Catheter - Medical Product Outsourcing

What are you searching for?

Sign in
OEM News

FDA OKs Teleflex’s Ringer Perfusion Balloon Catheter

According to the company, it’s the only commercially available percutaneous transluminal coronary angioplasty perfusion balloon.

Author Image

By: Sam Brusco

Associate Editor

Teleflex has gained U.S. Food and Drug Administration (FDA) 510(k) for its Ringer perfusion balloon catheter (PBC). According to the company, it’s the only commercially available percutaneous transluminal coronary angioplasty (PTCA) perfusion balloon.
 
The Ringer PBC is a rapid-exchange, 0.014” compatible catheter with a helical balloon at the working end. When inflated, the balloon approximates a hollow cylinder with a large central perfusion lumen. Teleflex said these characteristics allow continuous coronary blood flow during prolonged inflations.
 
The PBC is indicated for balloon dilatation of the coronary artery of coronary bypass graft stenoses, where distal blood perfusion during inflation is desired to improve myocardial perfusion. During PTCA the lumen is a passage for delivery of secondary devices.
 
Teleflex said the Ringer PBC will begin limited market release this month.
 
“The FDA 510(k) clearance of the Ringer Perfusion Balloon Catheter signifies a crucial achievement in Teleflex’s commitment to advancing medical innovation and improving patient outcomes,” said Teleflex Medical Director, Christopher Buller, MD. “We listen carefully to the challenges that interventionalists face daily and are proud, once again, to introduce a solution for unmet needs with this revolutionary PTCA perfusion balloon.”
 
In May, the company showcased findings from trials using the Prostatic Urethral Lift (PUL) with the UroLift System for benign prostatic hyperplasia (BPH).

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Add Medical Product Outsourcing as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics